Navigation Links
Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
Date:4/22/2008

/p>

"The study demonstrated the safety of long-term nitazoxanide exposure in patients with chronic hepatitis C. Importantly, this data suggests that thiazolides have an interferon-like mechanism and as a class may have a role as single agent therapy in some patients," said Dr. Emmet Keeffe, chief medical officer for Romark and co-author of the study.

-- An oral presentation by Brent Korba, Ph.D. of, Georgetown University

Medical Center, described preclinical studies showing that treatment of

cells harboring HCV replicons with nitazoxanide or its primary

metabolite, tizoxanide, does not induce viral mutations conferring

resistance to nitazoxanide, tizoxanide, interferon, ribavirin or 2'C-

methyl cytidine (a polymerase inhibitor). The presentation, titled,

"Studies of the Potential for Resistance to Nitazoxanide or Tizoxanide

in HCV-Containing Replicon Cell Lines," also demonstrated that

treatment of HCV replicon cells with tizoxanide potentiates the

antiviral effect of subsequent treatment with interferon (8-fold

decrease in concentration of interferon required to inhibit virus

replication by 90%).

"Data presented in each of these communications has provided important information in guiding the ongoing clinical development of nitazoxanide," said Dr. Rossignol.

Romark is currently enrolling patients for two U.S. clinical trials studying nitazoxanide for the treatment of hepatitis C genotype 1. For more information please visit please visit http://www.romarktrials.com or http://www.clinicaltrials.gov and enter the search term "nitazoxanide hepatitis United States."

About Nitazoxanide

Nitazoxanide belongs to a new class of small molecule cell signaling modulators (CSMs) called the thiazolides. Like interferons, thiaz
'/>"/>

SOURCE Romark Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... separating membrane market has witnessed robust development with the ... as a later starter. In 2012, the size of ... billion, with the proportion worldwide soaring to 16.3%. It is ... will continue its growth rate by around 20% in the ... to roughly RMB25 billion. An integrated membrane industrial ...
(Date:12/17/2014)... HOLBROOK, N.Y. , Dec. 17, 2014 /PRNewswire/ ... that The Depository Trust Company (DTC) has made ... the Deposit Chill on the Company,s stock effective ... of Northstar,s common stock for depository and book ... and the Company is now once again fully ...
(Date:12/17/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or the ... $125 million aggregate principal amount of 3.75% Convertible Senior ... and sold only to qualified institutional buyers pursuant to ... amended (the "Securities Act"). The Notes bear ... payable semiannually in arrears on June 15 and December ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... 2 Webmedx , the third largest ... a premier supplier of speech recognition and quality ... patient safety by announcing important changes to their ... speech-generated reports. The new changes bring Webmedx into ...
... 2 NewCardio (OTC Bulletin Board: NWCI ) ... Jr., NewCardio,s President and CEO, purchased 128,000 shares during his ... following the Company,s filing of its SEC Form 10-Q and ... "As discussed on our August 12, 2010 ...
Cached Medicine Technology:Webmedx Strengthens Quality Program and Improves Patient Safety in Compliance with New Industry Standards for Clinical Documentation 2Webmedx Strengthens Quality Program and Improves Patient Safety in Compliance with New Industry Standards for Clinical Documentation 3NewCardio CEO Increases Equity Position 2NewCardio CEO Increases Equity Position 3NewCardio CEO Increases Equity Position 4
(Date:12/20/2014)... (PRWEB) December 20, 2014 Dress company LunaDress ... dresses, and announced its Christmas Sale, offering big discounts on ... “Every girl has an idea to own a perfect wedding ... for your wedding dress, then come to LunaDress. Many different ... for you. Visit our website now and enjoy the current ...
(Date:12/20/2014)... 20, 2014 Recently, VogueQueen.com, a leading ... VogueQueen Big Sale Online for 2015. Great discounts ... new and old consumers can get a discount, up ... the company’s website before January 30, 2015. , VogueQueen.com ... and launched a prom dress promotion. Many customers worldwide ...
(Date:12/20/2014)... Francisco, CA (PRWEB) December 20, 2014 ... Social Innovation company just launched first birthday focused portal ... services, “MERRY BIRTHDAY MESSAGE” launched in both US and ... MERRY BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , MERRY ... for everyone’s birthday around the world. , Features, Choose ...
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men and ... other serious side effects will be consolidated in the ... pretrial proceedings, Wright & Schulte LLC reports. The U.S. ... Friday to transfer 21 Xarelto lawsuits and over 30 ... the Louisiana district court for coordination by Judge Eldon ...
(Date:12/19/2014)... Today, Balfleet.com , a leading ... its formal dress promotion. All the old and new ... off. , Balfleet.com is well-known for its high quality ... dresses, cocktail dresses and more. Its formal dresses are ... and they can create an elegant look when paired ...
Breaking Medicine News(10 mins):Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2
... initiated a worldwide recall on October 19, ... having Catalogue No.,10012-2555-001, serial numbers 488 or ... The current Instructions for Use state that,IVADs ... position or placed,in the paracorporeal (external) position. ...
... Various Shades of Colored Contact ... ... look with a new eye color? ACUVUE 2 COLOURS now,offers iMakeover(TM), a ... eye color a sneak peek of,what they would look like with different ...
... Revenue Increases 12%; Fully-Diluted EPS Increases to $0.89 per ... ... Methods Corporation,(Nasdaq: AIRM ) reported results for the quarter ended September ... year-ago,quarter. For the nine-month period, revenue increased 13% to $273.7,million, up from ...
... AG,a biopharmaceutical company developing Anticalins(R), a novel class ... of Dr,Angelika Stern as Chief Operating Officer to ... immediate effect of Dr Andreas Hohlbaum from,the position ... Chief,Technology Officer. The appointment of Dr Angelika ...
... Cell Therapeutics, Inc. (CTI),(Nasdaq and MTAX: CTIC) today reported recent ... September 30, 2007. Recent Events, -- Announced agreement ... first FDA-approved radioimmunotherapy, from Biogen Idec; this ... group of only a few biotech ...
... Industry Thought Leader Joins Healthcare ... Management Consulting Practice, SANTA ... announce the appointment of Ogan Gurel, M.D. as a Managing,Director ... Dr. Gurel join our team," said Vip Jain - Principal ...
Cached Medicine News:Health News:URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device 2Health News:ACUVUE(R) 2 COLOURS(R) Brand Contact Lenses Launches Virtual Eye Makeover Tool 2Health News:ACUVUE(R) 2 COLOURS(R) Brand Contact Lenses Launches Virtual Eye Makeover Tool 3Health News:Air Methods Reports 3Q2007 Results and 4Q2007 Update 2Health News:Air Methods Reports 3Q2007 Results and 4Q2007 Update 3Health News:Air Methods Reports 3Q2007 Results and 4Q2007 Update 4Health News:Air Methods Reports 3Q2007 Results and 4Q2007 Update 5Health News:Air Methods Reports 3Q2007 Results and 4Q2007 Update 6Health News:Air Methods Reports 3Q2007 Results and 4Q2007 Update 7Health News:Pieris Strengthens its Management, as it Prepares for the Clinical Development of PRS-050, an Anticalin(R)-Based Novel Cancer Therapy 2Health News:Pieris Strengthens its Management, as it Prepares for the Clinical Development of PRS-050, an Anticalin(R)-Based Novel Cancer Therapy 3Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results 2Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results 3Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results 4Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results 5Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results 6Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results 7Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results 8Health News:XRoads Solutions Group Appoints Dr. Ogan Gurel as Managing Director 2
Sterile Silicone Oil for Intraocular Application....
Round knurled handle, overall length 130 mm....
Optimum C/D/S Solution is a sterile cleaning, disinfecting, and storage solution for use with fluorosilicone acrylate and silicone acrylate rigid gas permeable (RGP) and hard contact lenses....
Hosford foreign body spud 4 3/4 inches, gouge blade 1 x 7 mm rounded tip, angled to left....
Medicine Products: